Interaction with other medicinal products and other forms of interaction
The veterinary medicinal product should not be used concomitantly with Ca-channel antagonists as maropitant has affinity to Ca-channels.
Maropitant is highly bound to plasma proteins and may compete with other highly bound medicines.
Use during pregnancy, lactation or lay
Use only according to the benefit-risk assessment by the responsible veterinarian
Conclusive reproductive toxicity studies have not been conducted in any animal species.
Special warnings for each target species
Vomiting can be associated with serious, severely debilitating conditions including gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be employed. Good veterinary practice indicates that antiemetics should be used in conjunction with other veterinary and supportive measures such as dietary control and fluid replacement therapy while addressing the underlying causes of the vomiting.
Dogs: Although maropitant has been demonstrated to be effective in both the treatment and prevention of emesis induced by chemotherapy, it was found more efficacious if used preventively. Therefore, it is recommended to administer the antiemetic prior to administration of the chemotherapeutic agent.
Cats: The efficacy of maropitant in reduction of nausea was demonstrated in studies using a model (xylazine induced nausea).
Adverse reactions (frequency and seriousness)
Dogs, cats:
Very common (1 animal / 10 animals treated):
Injection site pain.1,2
Very rare (1 animal / 10,000 animals treated, including isolated reports):
Anaphylactic-type reaction (allergic oedema, urticaria, erythema, collapse, dyspnoea, pale mucous membrane).
Lethargy.
Neurological disorders (ataxia, convulsion/seizure or muscle tremor).
1When injected subcutaneously to cat: moderate to severe response to injection (in approximately one third of cats).
2When injected subcutaneously to dog.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for contact details.
Overdose (symptoms, emergency procedures, antidotes), if necessary
Apart from transient reactions at the injection site following subcutaneous administration, maropitant was well tolerated in dogs and young cats injected daily with up to 5 mg/kg (5 times the recommended dose) for 15 consecutive days (3-times the recommended duration of administration). No data have been presented on overdoses in adult cats.
Major Incompatibilities
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.